GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Valuation Rank

NetraMark Holdings (XCNQ:AIAI) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NetraMark Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NetraMark Holdings (XCNQ:AIAI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Valuation Rank
Comparable Companies
TSXV:THNK XCNQ:HS TSXV:ADK TSXV:NEWU TSXV:DOC TSXV:NURS TSXV:CDX XCNQ:CGN TSXV:XYBN XCNQ:UDOC GEHC VEEV TSE:2413 HQY ASX:PME RCM TXG DOCS PGNY TDOC
Traded in Other Exchanges
AINMF:USA
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
Website
https://www.nurosene.com
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Andrew Parks Director